New Alliance, Bridge Bio And HitGen Target Cancer Treatments

Bridge Biotherapeutics, a biotechnology firm in the clinical stage, has entered into a strategic partnership with HitGen Inc., a prominent drug discovery company in China, to fast-track the development of new anticancer drugs. This collaboration builds on the success of initial hit identification using HitGen's DNA-encoded library (DEL) technology.

As Bridge Biotherapeutics seeks to broaden its oncology portfolio—currently centered on EGFR inhibitors for lung cancer—the company is exploring new drug targets in the fight against cancer. Significant resources have been allocated to advancing analytical methods aimed at discovering anticancer drugs with broad-spectrum efficacy. The partnership with HitGen is anticipated to accelerate the process of identifying, optimizing, and advancing lead compounds within the upcoming year.

HitGen's DEL platform, with its vast library of over 1.2 trillion small molecules, has demonstrated remarkable efficiency in drug discovery projects across the globe. The company's expertise spans DEL, synthetic therapeutic oligonucleotides (STO), targeted protein degradation (TPD), fragment-based drug discovery, and structure-based drug design, solidifying its position as a leader in the industry.

James Lee, CEO of Bridge Biotherapeutics mentioned, "By collaborating with HitGen, we will accelerate the discovery of new targeted anticancer drugs." He added, "We will challenge ourselves to develop drugs that can provide anticancer treatment effects even for genetically mutated cancers, which have been difficult to develop until now."

" We are pleased to collaborate with Bridge Biotherapeutics team in generating novel drug candidates based on the screening platform we possess. We will contribute to the acceleration of new anticancer drug discovery based on the expertise of both companies,” stated Dr. Jin Li, Chairman of the Board and CEO of HitGen Inc., expressed

Bridge Biotherapeutics is in the midst of a Phase 1 clinical trial for BBT-207, its leading drug candidate for treating non-small cell lung cancer. The collaboration with HitGen represents a major advancement in the company's mission to enhance its oncology portfolio and bring cutting-edge therapies to cancer patients.